Kornimate/medical-research-clean huggingface dataset:
smoking treatment in hiv clinical care settings

Conditions: Nicotine Dependence

Summary: the study is designed to evaluate and compare the efficacy and cost effectiveness of 3 smoking cessation treatments with hiv-positive cigarette smokers. the treatments include face-to-face individual counseling, a computer-internet-based self-help treatment and a self-help manual treatment.


Eligibility criteria:
inclusion criteria: * hiv positive * 18 years or older * smoking "most days" during the past month * must be able to read english exclusion criteria: * any contraindications for over-the-counter nicotine replacement treatment * active psychotic symptoms * severe cognitive deficits/dementia
evaluation of target organs damage in hypertensive patients

Conditions: Target Organs Damage; Hypertensive; no Known Cardiovascular; no Known Renal Disease

Summary: evaluation of target organs damage in hypertensive patients with no known cardiovascular (cv) or renal disease, stratified according to level of blood pressure control


Eligibility criteria:
inclusion criteria: * diagnosis of essential hypertension (treated or untreated); ht not discovered on the day of the consultation; no documented clinical cardiovascular or renal disease. exclusion criteria: -

Keywords: target organs damage hypertensive patients
pain and fatigue study

Conditions: Carcinoma

Summary: patients with advanced cancer who are undergoing chemotherapy and who report pain and fatigue at intake in the past 24 hours or at a level 2 or higher of pain or fatigue at a 3 or higher on a 10-point scale will be assigned randomly to an 8-week, 6-contact self management attention control (smac) intervention, or to a 8-week, 6-contact experimental patient intervention for management of symptoms and support (pimss) targeted toward symptom management, reducing impact on physical role and social functioning and emotional distress. both groups will continue to receive conventional cancer care. when compared with the self-management attention control intervention, patients exposed to the experimental intervention will report statistically significant positive effects on the following: 1. the primary outcome--total number of symptoms reported; 2. the secondary patient outcomes--reduced deterioration in physical role impact and social functioning, emotional distress, levels of communication with caregiver about care, and communication and satisfaction with provider care; and 3. caregiver outcomes--greater involvement in symptom management, increased mastery of the caregiving process, reduced levels of depression and burden.

goal: the primary goal of this research is to test a symptom management intervention, delivered by nurses with special training, using a stepped-care approach targeted toward pain and fatigue, followed by fifteen other prevalent cancer symptoms. second goals are to improve physical and social functioning, lower emotional distress, and improve communication with family caregiver in symptom management, and assist them to reduce their levels of depression and burden. this research is funded through a grant from the national cancer institutes, and builds upon the family care research team's program of supportive cancer-care research. outcomes: this study tests a stepped-approach intervention to determine if it improves symptom outcomes, especially pain and fatigue. secondary outcomes addressed by the intervention are physical role impact, social functioning, and emotional distress. these outcomes can have significant impact on patients and family caregivers' well-being as patients undergo chemotherapy. the shorter, more intense intervention corresponds to changes int he clinical management of cancer patient with more intense, shorter chemotherapy treatments; therefore, this intervention will be more easily translatable to the clinical setting.

Eligibility criteria:
inclusion criteria: * 21 years of age or older * solid tumor cancer diagnosis * receiving chemotherapy treatment * advanced cancer * family caregiver exclusion criteria * emotional or psychology disorder for which patient is receiving treatment * does not speak english * does not have access to a telephone * difficulty hearing on the telephone

Keywords: symptom management cancer chemotherapy treatment behavioral research physiological effects of drugs clinical trial, phase ii
trial of analgesia with lidocaine or extended-release oxycodone for neuropathic pain treatment in multiple sclerosis

Conditions: Neuropathic Pain; Chronic Pain; Multiple Sclerosis

Summary: this study will determine whether treatment with an extended-release opioid or topical lidocaine is effective in relieving distal symmetric lower extremity burning pain associated with multiple sclerosis (ms). if treatment with topical lidocaine is efficacious, it will have important implications for understanding this chronic pain syndrome, which is widely assumed to be caused by central nervous system pathology.

this study is a single-center, double-blind, 15-week, 3-period crossover clinical trial. subjects will complete each of the following 5-week long periods (unless they withdraw from the trial): 1) placebo pills and topical lidocaine patches, 2)extended-release oxycodone pills and placebo(vehicle) patches, and 3)placebo pills and placebo patches. sixty subjects will be randomized to one of 6 treatment sequences. it is expected that this trial will take approximately 2 years to complete.

Eligibility criteria:
inclusion criteria: * "definite ms" as defined by revised mcdonald criteria. * bilateral distal symmetric burning pain involving both feet for at least three months. * baseline weekly average pain rating equal to four or greater on 0-10 numerical scale. * stable ms medication and pain-related medications for 8 weeks prior to screening. * must come to research center for appointments exclusion criteria: * topical treatment with lidocaine, capsaicin, or other topical analgesics within 3 months prior to screening. * any treatment with opioid analgesics or tramadol within 3 months prior to screening. * hypersensitivity to lidoderm, lidocaine, or other local anesthetics. * hypersensitivity or inability to tolerate opioid analgesics. * current treatment with a total of 3 or more antidepressant or anticonvulsant drugs for pain. * current treatment with class i anti-arrhythmic agents at baseline. * beck depression inventory score \> 16 or clinically significant depression or dementia. * history of suicide attempt or current intent or plan. * history of excessive alcohol use or any illicit drug use within the past 2 years. * lack of adequate birth control in pre-menopausal women of childbearing age. * other pain more severe than lower extremity burning pain. * open skin lesions in the area where the lidocaine patch is to be applied. * cancer within the previous 5 years other than skin cancer. * ms exacerbation or any treatment with corticosteroids within 3 months prior to screening. * history of peripheral neuropathy, lower limb amputation, or another neuromuscular syndrome or systemic disorder known to be associated with sensory neuropathy. * does not meet criteria of baseline lab values at screening visit. * nerve conduction studies consistent with peripheral neuropathy.

Keywords: neuropathic pain chronic pain multiple sclerosis central neuropathic pain peripheral neuropathic pain opioid analgesic lidocaine
quality of life in managing chronic pain

Conditions: Chronic Low Back Pain

Summary: this study evaluates the use of a health-related quality of life report based on the spade cluster (sleep disturbance, pain interference with activities, anxiety, depression, and low energy/fatigue) derived from the promis-29 instrument in patients with chronic low back pain. half of the participants will receive the report, while the other half will not.

the health-related quality of life report provides participants with an overall score on the spade cluster and scores on each of its five component scales. the recently released federal pain research strategy states that pain cannot be measured in isolation, but rather should be assessed in conjunction with other outcome measures in 'non-pain domains,' such as quality of life. it recognizes that pain may be affected by, and affect, such patient attributes as sleep, mood, cognition, function, and quality of life. further, the report states that improvement in pain without concomitant improvement in other domains may not constitute a clinically meaningful outcome. this study aims to assess the utility of a health-related quality of life report in improving quality of life, back pain intensity, and back-related disability in participants with chronic low back pain.

Eligibility criteria:
inclusion criteria: chronic low back pain based on criteria established by the nih task force on research standards for chronic low back pain and spade cluster score ≥ 55 exclusion criteria: absence of chronic low back pain or spade cluster score \< 55
impact of periodontal supportive therapy in patients with gingivitis and periodontitis

Conditions: Gingivitis; Periodontitis

Summary: the study evaluated the number of sessions of periodontal supportive treatment in patients with gingivitis in order to evaluate the risk of periodontitis development.

patient with gingivitis were retrospectively evaluated. the number of periodontal supportive therapy were recorded other than gingivitis periodontal parameters over 5-years follow-up.

Eligibility criteria:
inclusion criteria: * diagnosis of gingivitis exclusion criteria: * diagnosis of periodontitis * pregnancy * systemic diseases
immunogenicity of a surface antigen, inactivated influenza vaccine formulation 2007-2008

Conditions: Influenza

Summary: due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to who and cpmp recommendations. immunogenicity and tolerability of the newly composed vaccines are subject for evaluation in a yearly clinical trial in non-elderly adults and elderly subjects (cpmp/bwp/214/96).


Eligibility criteria:
inclusion criteria: * healthy subjects eligible for enrollment into this study are male and female adult volunteers exclusion criteria: * any serious disease

Keywords: influenza vaccine
personal patient profile prostate (p4) randomized, multisite trial

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine whether or not participation in an experimental program called the "p4 program" is useful to men who are faced with choices about treatment for their early stage prostate cancer. the p4 program consists of a series of questions and information for the participant. before seeing the cancer specialist, participants will answer several questionnaires on a computer. this will take about 20-30 minutes. participants may choose to do this on a computer at home or on a touch-screen computer in the clinic. half the participants will then be shown several highly rated informational websites about prostate cancer treatments. the other half, based on the individual participant's answers, will receive the p4 program's customized written and on-screen information. reading the information and watching videos will take about 20 minutes. about one month later, and again 6 months, participants will complete follow-up questionnaires electronically or by mail. these questionnaires will help us understand how each participant's decision for treatment of their prostate cancer went. answering these questionnaires should take about 20 minutes each time.


Eligibility criteria:
inclusion criteria: * biopsy-proven diagnosis of prostate cancer, stage i or ii * diagnosis within the past 6 months * has appointment with a consulting specialist at one of the clinical trial sites * must be able to read and write english or spanish at a 6th grade level * must not have begun any treatment (except watchful waiting) * must be able to complete baseline assessment before target clinician visit. exclusion criteria: * advanced prostate cancer * diagnosed more than 6 months ago * cannot read and write english or spanish at a 6th grade level * does not have appointment at one of the clinical trial sites

Keywords: localized prostate cancer treatment decision making tailored decision aid
pregabalin versus dexmedetomidine for delirium treatment after coronary artery bypass grafting

Conditions: Pregabalin; Delirium Treatment; Coronary Artery Bypass Grafting; Dexmedetomidine

Summary: the aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after coronary artery bypass grafting.

delirium is an acute brain disorder that involves changes in consciousness, attention, cognition, and perception.the incidence of postoperative delirium (pod) is high among patients undergoing cardiac surgery, ranging from 20 to 50%, and the risk is even higher in the elderly.

Eligibility criteria:
inclusion criteria: * cabg patients ≥ 65 years of age both genders american society of anesthesiologists (asa) physical status classification ii or iii planned for fast track developed postoperative delirium (pod). exclusion criteria: * patients who had history of psychiatric diseases; inability to communicate; * previous history of pod; preoperative sick sinus syndrome, allergy/sensitivity to pregabalin or dexmedetomidine, severe bradycardia (heart rate \<50 beat per minute), second-degree or above atrioventricular block without pacemaker; severe hepatic or renal insufficiency. * previous cardiac or thoracic surgery, known diagnosis of depression or other major psychiatric diseases, cognitive impairment or inability to cooperate with the study, renal insufficiency, and history of substance abuse.
hypoalgesic effects neural mobilization techniques

Conditions: Hyperalgesia

Summary: the purpose of this study was to evaluate the immediate mechanical hypoalgesic effect of neural mobilization in asymptomatic subjects. we also compared neural gliding versus neural stretching to see which produced greater hypoalgesic effects in asymptomatic subjects.

asymptomatic subjects will be randomly allocated into three groups: the neural glide group; the neural stretch group; and the placebo group. each subject will receive one treatment session. outcome measures included bilateral pressure pain threshold measured at the trigeminal, cervical, and tibialis anterior points, which will assess pre-treatment and immediately post-treatment by a blinded assessor. three-way repeated measures analysis of variance was used to evaluate changes in pressure pain threshold, with group (experimental or control) as the between-subjects variable and time (pre-, post-treatment) or side (dominant, nondominant) as the within-subjects variable.

Eligibility criteria:
inclusion criteria: * asymptomatic subjects who met the inclusion criterion of being between 18 and 30 years old. exclusion criteria: * rheumatologic diseases or any type of cancer, cervical surgery in the past, whiplash trauma and undergoing any type of treatment like physical therapy, manual therapy, osteopathy, chiropraxis, acupuncture during the last three months. all patients recruited for the study complained of pain localized in the neck and/or head region. initial screening was accomplished by telephone and eligible persons attended a evaluation appointment. * development of systemic or degenerative diseases * subjects with symptoms of depression according beck's questionnaire * pain in any area between the lower back and head in the last 9 months * traumatic event in the past 12 months * history of neck or face pain in the last 6 months

Keywords: neural mobilization physical therapy asymptomatic subjects
a double-blind, group-comparison p-iii study with zolpidem mr using placebo and nitrazepam in insomnia patients

Conditions: Sleep Initiation and Maintenance Disorders

Summary: a multicenter, randomized, double-blind, triple-dummy, group-comparison study using placebo and nitrazepam as a comparative drug.


Eligibility criteria:
inclusion criteria: * nonorganic insomnia associated with schizophrenia and manic-depressive psychosis. exclusion criteria: * patients with allergic reactions to zolpidem or nitrazepam; patients with serious cardiac disorders; serious hepatic impairment; serious renal diseases.

Keywords: insomnia schizophrenia manic-depressive psychosis zolpidem
effect of foot muscles training and foot orthosis on the medial arch in flatfoot subjects

Conditions: Flexible Flatfoot

Summary: orthotic therapy or exercise therapy is the standard conservative treatment for flexible flat foot. little is known about the effectiveness of their interaction on managing flatfoot. the study aims to evaluate the effect of insoles and short foot exercise on the height and area of the medial longitudinal arch of flexible flatfoot participants as well as the force and pressure.

study design: a parallel, active-control study design was used to conduct a single-blinded randomized controlled trial. method: the toe rising test, the "too many toes" sign, and the navicular drop test was used to select 30 participants with flexible flatfoot. participants was randomly assigned either to an experimental group (n = 15) or a control group (n = 15). the experimental group received short foot exercises (sfe) and insoles, and the control group received only insoles. sfe was implemented 30 times for a duration of three minutes each day over the course of six weeks. the exercise progressed from sitting to standing and finally to one leg stance position within every two weeks. the participants wore shoes containing orthotic insoles for eight hours per day for six weeks. the emed-x system was used to measure plantar pressure distribution (force, area, and pressure) at baseline and at two-week intervals throughout the six-week intervention. the lower extremity functional scale (lefs) was used to evaluate restriction in participants' functional abilities, and the navicular drop test (ndt) was used to assess the medial longitudinal arch (mla) height. both variables were measured at baseline and at the sixth week. statistics: mixed-effects anova was used to test for significant interactions between the two groups across time and within-subject observations of the outcomes.

Eligibility criteria:
inclusion criteria: * females and males aged between 18 and 36 * bilateral symptomatic flexible flatfoot, with symptoms including foot pain and lower limb fatigue * participants must show positive physical examination findings, including a positive result for the "too many toes" sign, the navicular drop test, and the foot toe raising test (carr et al., 2016). a positive result for the "too many toes" sign occurs when more toes can be seen on the lateral side of each foot due to external rotation and abduction of the feet, and the positive result for the toe rising test is the reconstruction of the medial longitudinal arch secondary to the tightness of the plantar fascia (carr et al., 2016). a positive result for the navicular drop test is an arch height more than or equal to 10 mm(aenumulapalli et al., 2017) exclusion criteria: * an anatomical discrepancy in leg length * pathologic or neurologic disorders of the feet * a history of traumatic foot injury or surgery within the last six months * history of wearing foot orthoses within the past two years

Keywords: flatfoot insole short-foot exercise orthotic
a study to examine the safety, tolerability, and body weight effect of pramlintide alone and in combination with oral antiobesity agents in overweight and obese subjects

Conditions: Overweight; Obesity

Summary: this study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.


Eligibility criteria:
inclusion criteria: * is obese with a body mass index (bmi) \>=30 kg/m\^2 to \ =27 kg/m\^2 in the presence of other risk factors (e.g., hyperlipidemia, sleep apnea, or treatment for these conditions) * has been obese or overweight for at least one year prior to study start * either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to study start: \*hormone replacement therapy; \*oral contraceptives; \*lipid-lowering agents; \*thyroid replacement therapy; \*metformin exclusion criteria: * is currently enrolled in or is planning to enroll in a formal weight-loss program * is unwilling or unable to participate in a lifestyle intervention program as part of the study * has been treated (within the 2 months prior to study start), is currently treated, or is expected to require or undergo treatment with any of the following excluded medications: \*prescription or over the counter antiobesity agents (within the 6 months prior to study start); \*psychotropic/neurological agents (i.e., antipsychotic, antiepileptic, antidepressant, or antianxiety agents, or mood stabilizers); \*steroids that are known to result in high systemic absorption; \*calcitonin; \*ketoconazole; \*antidiabetic medications * has had liposuction, abdominoplasty, or a similar procedure within 1 year before study start or is planning to have such a procedure during the study * has received any investigational drug within 1 month (or 5 half-lives of investigational drug, whichever is greater) before study start * has previously used pramlintide either by prescription or as part of a clinical study * has used sibutramine or phentermine (either by prescription or as part of a clinical study) within 2 years before study start * has donated blood within 2 months before study start, or is planning to donate blood during the study

Keywords: overweight obesity pramlintide symlin sibutramine meridia phentermine amylin